Press releases

19 Mar 2019

Transparency notification BlackRock, Inc.

11 Mar 2019

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

28 Feb 2019

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study 

28 Feb 2019

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

27 Feb 2019

UCB Full Year Report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipeline

15 Feb 2019

UCB builds on its R&D footprint to form a research satellite facility within King’s College London

Press releases

Press releases

Search Press releases

Transparency notification BlackRock, Inc.

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

UCB Full Year Report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipeline

UCB builds on its R&D footprint to form a research satellite facility within King’s College London

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Transparency notification BlackRock, Inc.

Arthritis &amp; Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study&nbsp;

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

UCB Full Year Report 2018:&nbsp;2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipeline

UCB builds on its R&amp;D footprint to form a research satellite facility within King’s College London

Choose a Country

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

UCB Full Year Report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipeline

UCB builds on its R&D footprint to form a research satellite facility within King’s College London